ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation Press release LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the company’s investigational drug QR-110 has received orphan drug designation (ODD) from both the U.S. June 01, 2016